CN113924288A - 一种含喹啉基化合物、药物组合物以及其用途 - Google Patents

一种含喹啉基化合物、药物组合物以及其用途 Download PDF

Info

Publication number
CN113924288A
CN113924288A CN202080026629.7A CN202080026629A CN113924288A CN 113924288 A CN113924288 A CN 113924288A CN 202080026629 A CN202080026629 A CN 202080026629A CN 113924288 A CN113924288 A CN 113924288A
Authority
CN
China
Prior art keywords
radical
group
oxy
fluorophenyl
cyclopropane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080026629.7A
Other languages
English (en)
Other versions
CN113924288B (zh
Inventor
吴伟
祝力
杨艳青
胡伟
张慧
董长新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Puqi Medicine Technology Co ltd
Original Assignee
Beijing Puqi Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Puqi Medicine Technology Co ltd filed Critical Beijing Puqi Medicine Technology Co ltd
Publication of CN113924288A publication Critical patent/CN113924288A/zh
Application granted granted Critical
Publication of CN113924288B publication Critical patent/CN113924288B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

提供了一种如通式(Ⅰ)或(II)所示的含喹啉基的化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、同位素标记物或异构体，还提供了包含其的药物组合物以及所述化合物、药物组合物的用途。提供的化合物具有双重分子功能，可作为一类酪氨酸激酶/组蛋白去乙酰化酶的多靶点抑制剂，能够同时起到两类抑制剂的效果，具有优异的生物活性及药代动力学性能，尤其在肿瘤的治疗领域非常具有应用潜力。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202080026629.7A 2019-04-03 2020-03-30 一种含喹啉基化合物、药物组合物以及其用途 Active CN113924288B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910266681 2019-04-03
CN2019102666819 2019-04-03
PCT/CN2020/082041 WO2020200160A1 (zh) 2019-04-03 2020-03-30 一种含喹啉基化合物、药物组合物以及其用途

Publications (2)

Publication Number Publication Date
CN113924288A true CN113924288A (zh) 2022-01-11
CN113924288B CN113924288B (zh) 2024-04-05

Family

ID=72664700

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080026629.7A Active CN113924288B (zh) 2019-04-03 2020-03-30 一种含喹啉基化合物、药物组合物以及其用途

Country Status (10)

Country Link
US (1) US20220162184A1 (zh)
EP (1) EP3950677A4 (zh)
JP (1) JP7423655B2 (zh)
KR (1) KR102690225B1 (zh)
CN (1) CN113924288B (zh)
AU (1) AU2020255702B2 (zh)
BR (1) BR112021019491A2 (zh)
CA (1) CA3135921C (zh)
MX (1) MX2021012124A (zh)
WO (1) WO2020200160A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors
CN114573553B (zh) * 2022-01-27 2023-11-10 广州六顺生物科技有限公司 杂芳环类衍生物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053908A1 (en) * 2000-10-20 2004-03-18 Yasuhiro Funahashi Nitrogen-containing aromatic derivatives
US20070027184A1 (en) * 2005-07-29 2007-02-01 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
CN102408411A (zh) * 2011-09-19 2012-04-11 广州盈升生物科技有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
WO2018072614A1 (zh) * 2016-10-18 2018-04-26 北京康辰药业股份有限公司 一种喹啉基取代的羧酸化合物或其药学上可接受的盐、其药物组合物及应用
WO2018226542A1 (en) * 2017-06-09 2018-12-13 Arvinas, Inc. Modulators of proteolysis and associated methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7340096A (en) * 1995-11-07 1997-05-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
CN105131082A (zh) * 2015-09-17 2015-12-09 广州康缔安生物科技有限公司 环肽类化合物及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053908A1 (en) * 2000-10-20 2004-03-18 Yasuhiro Funahashi Nitrogen-containing aromatic derivatives
CN101024627A (zh) * 2000-10-20 2007-08-29 卫材R&D管理有限公司 含氮芳环衍生物
US20070027184A1 (en) * 2005-07-29 2007-02-01 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
CN102408411A (zh) * 2011-09-19 2012-04-11 广州盈升生物科技有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
WO2018072614A1 (zh) * 2016-10-18 2018-04-26 北京康辰药业股份有限公司 一种喹啉基取代的羧酸化合物或其药学上可接受的盐、其药物组合物及应用
WO2018226542A1 (en) * 2017-06-09 2018-12-13 Arvinas, Inc. Modulators of proteolysis and associated methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARIANA C. F. SEGRETTI等: "Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function", vol. 6, pages 1156, XP055410042, DOI: 10.1021/acsmedchemlett.5b00303 *
PRAVEER K. GUPTA等: "Inhibitors selective for HDAC6 in enzymes and cells", vol. 20, pages 7067 - 7070, XP027459359, DOI: 10.1016/j.bmcl.2010.09.100 *
巴德年主编, vol. 1, 黑龙江科学技术出版社, pages: 299 - 302 *

Also Published As

Publication number Publication date
JP7423655B2 (ja) 2024-01-29
JP2022528109A (ja) 2022-06-08
MX2021012124A (es) 2021-12-10
CA3135921A1 (en) 2020-10-08
US20220162184A1 (en) 2022-05-26
WO2020200160A1 (zh) 2020-10-08
EP3950677A4 (en) 2023-01-11
CA3135921C (en) 2024-04-16
BR112021019491A2 (pt) 2021-11-30
KR20210148296A (ko) 2021-12-07
AU2020255702B2 (en) 2023-04-13
KR102690225B1 (ko) 2024-07-30
EP3950677A1 (en) 2022-02-09
CN113924288B (zh) 2024-04-05
AU2020255702A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
ES2615238T3 (es) Derivados de tetrahidroquinolinas como inhibidores de bromodominio
ES2651730T3 (es) Moduladores c-Met y métodos de uso
KR101896599B1 (ko) 브로모도메인 억제제로서 유용한 테트라하이드로퀴놀린 유도체
JP6407955B2 (ja) クマリン誘導体、ならびに過剰増殖疾患を治療する際の使用方法
TW201625620A (zh) 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
CN113924288A (zh) 一种含喹啉基化合物、药物组合物以及其用途
CA2871453A1 (en) Quinazolinedione derivative
CN111417628A (zh) 作为ehmt2抑制剂的胺取代的杂环化合物、其盐及其合成方法
CN111303121A (zh) 含喹喔啉酮的4-苯氧基吡啶类化合物及其应用
US11548900B2 (en) Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof
CA2886744A1 (en) Imatinib derivatives, their preparation and use to treat cancer and bacterial and viral infections
CN113880772B (zh) 一类cdk激酶抑制剂及其应用
KR20190003765A (ko) 신규 2,4,6-트리치환된-s-트리아진 화합물, 그 제조방법 및 용도
US11999747B2 (en) Furoquinolinediones as inhibitors of TDP2
CN102149678A (zh) 用于治疗癌症的新型邻氨基酰苯胺类
JP2021191784A (ja) ピロリジン化合物
JP2022550489A (ja) スルホ置換ビアリール化合物又はその塩並びにその調製方法及び使用
RU2803116C2 (ru) Хинолинил-содержащее соединение и его фармацевтическая композиция и применение
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
CN111440177B (zh) 一种取代吡唑并[1,5-a]嘧啶类化合物及其制备方法和应用
WO2022166990A1 (zh) 用于抗肿瘤的药物组合
WO2024094016A1 (zh) 一种二噁烷并喹啉类化合物的盐、其晶型以及它们的制备方法及应用
WO2022174803A1 (zh) 含s构型的氨基苯甲酰胺基哒嗪酮类化合物、其制备方法、药物组合物及应用
CN103012274B (zh) 异羟肟酸类化合物，制备方法和用途
EA045074B1 (ru) Соединения пирролидина

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Room 608, floor 6, building 2, No. 13 yard, Hangfeng Road, Fengtai District, Beijing 100070

Applicant after: Beijing Puqi Pharmaceutical Technology Co.,Ltd.

Address before: 100070 6th floor, block B, Chongxin building, No. 13, Hangfeng Road, Fengtai District, Beijing

Applicant before: BEIJING PUQI MEDICINE TECHNOLOGY Co.,Ltd.

GR01 Patent grant
GR01 Patent grant